SCN5A Variant F4S
Summary of observed carriers, functional annotations, and structural context for SCN5A F4S. Data combine curated literature, international cohorts, and gnomAD observations.
Estimated LQT3 penetrance
33%
1/10 effective observations
Estimated BrS1 penetrance
10%
0/10 effective observations
Total carriers
0
0 BrS1 · 0 LQT3 · 0 unaffected
Variant features alone are equivalent to phenotyping 0 individuals for Brugada syndrome and 1 individuals for LQT3.
In silico predictors
| PROVEAN | PolyPhen-2 | BLAST-PSSM | REVEL | Penetrance Density BrS (%) | Penetrance Density LQT3 (%) |
|---|---|---|---|---|---|
| NA | NA | NA | 0.441 | 7 | 44 |
PROVEAN scores below -2 suggest deleterious impact. REVEL scores above 0.5–0.75 are often interpreted as likely pathogenic. PolyPhen-2 scores above 0.85 are typically pathogenic. Penetrance density summarises neighbouring residue risk (Kroncke et al. 2019).
Reported carrier data
| Source | Year | Carriers | Unaffected | LQT3 | BrS1 | Other | Other Disease |
|---|---|---|---|---|---|---|---|
| Literature, cohort, and gnomAD | – | 0 | 0 | 0 | 0 | – | |
| Variant features alone | – | 15 | 14 | 1 | 0 | – | – |
Totals may differ from individual publications due to duplicate patients removed during curation.
Nearby variants
Neighbouring residues within 15 Ångström provide structural context. Variants listed in the right-most column have been observed clinically or in gnomAD.
| Neighbour residue | Distance (Å) | Observed variants |
|---|---|---|
| 1 | 7 | c.-53+1G>A, M1I, |
| 2 | 5 | A2T, |
| 3 | 4 | N3S, N3K, N3K, |
| 4 | 0 | F4V, |
| 5 | 4 | |
| 6 | 5 | L6S, |
| 7 | 7 | P7R, P7L, |
| 8 | 8 | R8W, R8Q, R8P, |
| 9 | 8 | G9S, G9V, |
| 10 | 9 | T10S, T10S, |
| 11 | 10 | S11R, S11R, S11R, |
| 12 | 11 | |
| 13 | 11 | |
| 14 | 12 | R14S, R14C, R14H, |
| 15 | 13 | R15G, R15T, R15M, |
| 16 | 13 | F16L, F16L, F16L, |
| 17 | 14 | |
| 18 | 14 | R18W, R18Q |
| 19 | 15 |